On September 12, 2022 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, reported that its collaborator, Bristol Myers Squibb, reported that updated Phase 1 results with BMS-986249, a Probody therapeutic version of ipilimumab, the anti-CTLA-4 antibody, at the ESMO (Free ESMO Whitepaper) Congress 2022 in Paris, France (Press release, CytomX Therapeutics, SEP 12, 2022, View Source [SID1234619414]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"BMS-986249 is a conditionally activated CTLA-4-targeting antibody that has shown clinical activity in multiple tumor types, and the safety profile and disease control rate observed in the updated Phase 1 data for BMS-986249 with and without nivolumab is promising. BMS-986249 appears to be tolerated at higher doses than traditional ipilimumab dosing, and we are encouraged by the report of a complete response in melanoma and a case study of a partial response in microsatellite-stable colorectal cancer. This Phase 1 study set the stage for the ongoing randomized Phase 2 trial of BMS-986249 in melanoma evaluating the potential differentiation of the Probody from ipilimumab, and we look forward to results from this study in due course," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics.